By Fineline Cube Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Roche (SWX: ROP, OTCMKTS: RHHBY) announced today a comprehensive global collaboration to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton’s tyrosine kinase (BTK), with potential total payments to Nurix of up to $2.3 billion.
Partnership Structure
| Component | Detail |
|---|---|
| Upfront Payment | $700 million to Nurix |
| Total Potential Value | Up to $2.3 billion (including milestones) |
| Development Cost Sharing | Nurix 40% / Roche 60% |
| U.S. Profit/Loss Split | 50/50 between parties |
| U.S. Commercialization | Co-commercialization across all indications |
| Ex-U.S. Commercialization | Roche-led with Nurix receiving royalties (low- to high-teens %) |
Therapeutic Development Strategy
Malignant Hematology Focus
- CLL: Execution of previously disclosed pivotal Phase 2 and Phase 3 trials
- Additional Indications: Multiple label-enabling studies as monotherapy and in combination regimens
Immune-Mediated Diseases Expansion
- Multiple Sclerosis (MS): Phase 2 clinical trial planned
- Chronic Spontaneous Urticaria (CSU): Phase 2 clinical trial planned
- Additional Immunology Indications: Under evaluation
Strategic Rationale
- Complementary Expertise: Combines Nurix’s pioneering targeted protein degradation platform with Roche’s established B-cell targeted therapy portfolio
- Infrastructure Leverage: Utilizes Roche’s global clinical development and commercial infrastructure
- Therapeutic Breadth: Unprecedented expansion of BTK degradation across three major therapeutic areas
- Commercial Synergy: Aligns with Roche’s existing hematology and immunology commercial operations
Market Context
- BTK Inhibitor Market: Currently valued at $12.5 billion globally with projected growth to $18.7 billion by 2030
- Differentiation Opportunity: Oral degraders may overcome limitations of current covalent and non-covalent BTK inhibitors
- Competitive Landscape: Bexobrutideg represents one of the most advanced oral BTK degraders in clinical development
- Royalty Structure: Nurix’s ex-U.S. royalty rates position the company to benefit significantly from global sales potential
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development plans, regulatory pathways, commercial expectations, and financial projections. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech